Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

4E-BP1, a multifactor regulated multifunctional protein.

Qin X, Jiang B, Zhang Y.

Cell Cycle. 2016 Mar 18;15(6):781-6. doi: 10.1080/15384101.2016.1151581.

PMID:
26901143
2.

mTOR-Dependent and Independent Survival Signaling by PI3K in B Lymphocytes.

Kaileh M, Vazquez E, MacFarlane AW 4th, Campbell K, Kurosaki T, Siebenlist U, Sen R.

PLoS One. 2016 Jan 19;11(1):e0146955. doi: 10.1371/journal.pone.0146955. eCollection 2016.

3.

Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.

An N, Xiong Y, LaRue AC, Kraft AS, Cen B.

Cancer Res. 2015 Dec 15;75(24):5318-28. doi: 10.1158/0008-5472.CAN-15-0544.

PMID:
26670562
4.

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.

Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.

Oncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.

5.

MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.

Cai Q, Medeiros LJ, Xu X, Young KH.

Oncotarget. 2015 Nov 17;6(36):38591-616. doi: 10.18632/oncotarget.5774. Review.

6.

Targeting the Pim kinases in multiple myeloma.

Keane NA, Reidy M, Natoni A, Raab MS, O'Dwyer M.

Blood Cancer J. 2015 Jul 17;5:e325. doi: 10.1038/bcj.2015.46. Review.

7.

Pim-2 Modulates Aerobic Glycolysis and Energy Production during the Development of Colorectal Tumors.

Zhang XH, Yu HL, Wang FJ, Han YL, Yang WL.

Int J Med Sci. 2015 Jun 8;12(6):487-93. doi: 10.7150/ijms.10982. eCollection 2015.

8.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S.

Semin Cancer Biol. 2015 Dec;35 Suppl:S25-54. doi: 10.1016/j.semcancer.2015.02.006. Epub 2015 Apr 17. Review.

9.

Pim kinases in hematological malignancies: where are we now and where are we going?

Mondello P, Cuzzocrea S, Mian M.

J Hematol Oncol. 2014 Dec 10;7:95. doi: 10.1186/s13045-014-0095-z. Review.

10.

A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, Albertson DJ, Call LT, Bearss JJ, Tripp S, Liu T, Stephens BJ, Mollard A, Warner SL, Bearss DJ, Kanner SB.

Neoplasia. 2014 May;16(5):403-12. doi: 10.1016/j.neo.2014.05.004. Epub 2014 Jun 18.

11.

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D.

Blood. 2014 Feb 6;123(6):905-13. doi: 10.1182/blood-2013-04-495366. Epub 2013 Dec 20.

12.

Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells.

Yu Z, Zhao X, Huang L, Zhang T, Yang F, Xie L, Song S, Miao P, Zhao L, Sun X, Liu J, Huang G.

J Biol Chem. 2013 Dec 6;288(49):35406-16. doi: 10.1074/jbc.M113.508226. Epub 2013 Oct 18.

13.

Interleukin-6 expands homeostatic space for peripheral T cells.

Hong C, Nam AS, Keller HR, Ligons DL, Park JY, Yoon HW, Park JJ, Luckey MA, Park JH.

Cytokine. 2013 Nov;64(2):532-40. doi: 10.1016/j.cyto.2013.08.001. Epub 2013 Aug 26.

14.

Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.

Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S317-29. doi: 10.1016/j.clml.2013.05.019. Epub 2013 Aug 27.

15.

Cell and gene therapy for severe heart failure patients: the time and place for Pim-1 kinase.

Siddiqi S, Sussman MA.

Expert Rev Cardiovasc Ther. 2013 Aug;11(8):949-57. doi: 10.1586/14779072.2013.814830. Review.

16.

Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.

Lee SJ, Han BG, Cho JW, Choi JS, Lee J, Song HJ, Koh JS, Lee BI.

PLoS One. 2013 Jul 31;8(7):e70358. doi: 10.1371/journal.pone.0070358. Print 2013.

17.

The PIM-2 kinase is an essential component of the ultraviolet damage response that acts upstream to E2F-1 and ATM.

Zirkin S, Davidovich A, Don J.

J Biol Chem. 2013 Jul 26;288(30):21770-83. doi: 10.1074/jbc.M113.458851. Epub 2013 Jun 11.

18.

Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.

Narlik-Grassow M, Blanco-Aparicio C, Cecilia Y, Perez M, Muñoz-Galvan S, Cañamero M, Renner O, Carnero A.

PLoS One. 2013;8(4):e60277. doi: 10.1371/journal.pone.0060277. Epub 2013 Apr 2. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/1b8b6002-4e0f-4c5d-8ae8-fd45447b6149. Renner, Oliver [added].

19.

SYK regulates mTOR signaling in AML.

Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.

Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.

20.

Inhibition of Pim2-prolonged skin allograft survival through the apoptosis regulation pathway.

Liu H, Zhang C, Liang T, Song J, Hao J, Hou G.

Cell Mol Immunol. 2012 Nov;9(6):503-10. doi: 10.1038/cmi.2012.41. Epub 2012 Oct 22.

Items per page

Supplemental Content

Write to the Help Desk